Table 3.
Sex-specific predictors of all-cause mortality with univariate Cox regression analysis.
| Mortality univariates | Men | Women | ||
|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | |
| Age (year) | 1.66 (1.19–2.33) | 0.003 | 1.2 (0.59–2.44) | 0.62 |
| BMI | 0.96 (0.68–1.36) | 0.84 | 1.4 (0.74–2.65) | 0.30 |
| Atrial fibrillation | 1.18 (0.9–1.53) | 0.22 | 1.21 (0.69–2.11) | 0.51 |
| Hypertension | 0.91 (0.7–1.19) | 0.49 | 0.7 (0.42–1.17) | 0.17 |
| Diabetes | 1.09 (0.83–1.42) | 0.54 | 1.77 (1.1–2.84) | 0.02 |
| COPD | 1.23 (0.98–1.55) | 0.07 | 0.75 (0.34–1.63) | 0.46 |
| SCD | 1.13 (0.87–1.45) | 0.36 | 1.16 (0.67–2.0) | 0.59 |
| CAD | 1.18 (0.86–1.63) | 0.31 | 0.98 (0.55–1.76) | 0.94 |
| PCI | 1.07 (0.81–1.41) | 0.62 | 1.23 (0.7–2.16) | 0.48 |
| CABG | 1.19 (0.92–1.53) | 0.19 | 0.01 (0.0–inf) | 0.99 |
| AMI | 1.14 (0.84–1.53) | 0.40 | 0.99 (0.55–1.79) | 0.98 |
| ICD | 1.14 (0.84–1.54) | 0.41 | 0.7 (0.41–1.2) | 0.20 |
| CRT | 1.47 (1.15–1.87) | 0.002 | 1.86 (1.15–3.01) | 0.01 |
| NYHA ≥3 | 1.27 (0.98–1.65) | 0.07 | 1.01 (0.55–1.85) | 0.98 |
| DCM | 1.35 (0.97–1.86) | 0.07 | 1.08 (0.59–1.96) | 0.81 |
| iDCM | 1.31 (0.55–3.12) | 0.54 | 0.67 (0.15–2.99) | 0.60 |
| niDCM | 0.77 (0.32–1.83) | 0.55 | 1.50 (0.34–6.72) | 0.60 |
| LVEF (%) | 0.58 (0.42–0.8) | 0.001 | 1.13 (0.64–2.0) | 0.67 |
| LVEDD (mm) | 1.31 (1.0–1.71) | 0.054 | 1.39 (0.7–2.74) | 0.35 |
| LVESD (mm) | 1.41 (1.06–1.87) | 0.02 | 1.26 (0.62–2.59) | 0.52 |
| RVEDD (mm) | 1.08 (0.83–1.42) | 0.56 | 0.87 (0.46–1.65) | 0.67 |
| TAPSE (mm) | 0.74 (0.54–1.0) | 0.053 | 0.87 (0.45–1.68) | 0.67 |
| E/A ratio | 1.35 (0.99–1.84) | 0.06 | 0.96 (0.5–1.85) | 0.90 |
| DT (ms) | 0.46 (0.3–0.68) | 0.0001 | 0.64 (0.25–1.61) | 0.34 |
| PASP (mmHg) | 1.16 (0.85–1.59) | 0.35 | 0.92 (0.5–1.69) | 0.78 |
| MR 1–2 | 1.05 (0.79–1.4) | 0.74 | 0.45 (0.23–0.88) | 0.02 |
| MR 3–4 | 1.16 (0.89–1.5) | 0.26 | 2.2 (1.21–3.99) | 0.01 |
| TR 1–2 | 1.15 (0.85–1.55) | 0.38 | 0.92 (0.51–1.66) | 0.79 |
| TR 3–4 | 1.07 (0.83–1.38) | 0.59 | 1.12 (0.63–1.99) | 0.70 |
| LV aneurysm | 1.05 (0.8–1.38) | 0.74 | 1.27 (0.74–2.18) | 0.39 |
| Hemoglobin (g/L) | 0.8 (0.63–1.02) | 0.07 | 0.69 (0.37–1.3) | 0.26 |
| Creatinine (μmol/L) | 1.27 (1.09–1.49) | 0.003 | 1.0 (0.55–1.83) | 0.99 |
| GFR (ml/min/1.73 m2) | 0.64 (0.46–0.89) | 0.007 | 1.03 (0.58–1.81) | 0.93 |
| Glucose (mmol/L) | 1.06 (0.82–1.38) | 0.65 | 2.94 (1.47–5.86) | 0.002 |
| Furosemide | 1.72 (1.23–2.42) | 0.002 | 1.23 (0.64–2.36) | 0.53 |
| ACEi/ARB | 1.2 (0.85–1.69) | 0.31 | 0.5 (0.31–0.81) | 0.005 |
| Statin | 1.06 (0.8–1.42) | 0.68 | 0.82 (0.45–1.49) | 0.52 |
| MRA | 1.58 (1.16–2.17) | 0.004 | 1.2 (0.64–2.26) | 0.56 |
| Amiodarone | 1.07 (0.81–1.42) | 0.64 | 1.19 (0.62–2.27) | 0.61 |
| Beta blocker | 0.98 (0.75–1.29) | 0.90 | 0.96 (0.53–1.77) | 0.90 |
| AAD resistance | 1.16 (0.86–1.56) | 0.32 | 1.21 (0.61–2.41) | 0.59 |
| ICD shock | 1.16 (0.88–1.53) | 0.29 | 1.56 (0.87–2.79) | 0.14 |
| HD instability | 1.0 (0.76–1.32) | 0.99 | 2.3 (1.19–4.43) | 0.01 |
| Incessant VT | 1.27 (0.97–1.66) | 0.08 | 1.33 (0.76–2.31) | 0.32 |
| Electrical storm | 1.21 (0.95–1.53) | 0.13 | 1.87 (1.15–3.02) | 0.01 |
| Cumulative ICD therapies | 1.21 (0.92–1.6) | 0.16 | 0.92 (0.5–1.69) | 0.79 |
| Electrical storm/incessant VT | 1.29 (0.98–1.69) | 0.07 | 1.76 (0.96–3.22) | 0.07 |
| Electrical storm/cumulative ICD therapies | 2.01 (1.13–3.55) | 0.02 | 1.49 (0.46–4.90) | 0.51 |
| Transseptal | 1.2 (0.95–1.52) | 0.13 | 0.95 (0.48–1.86) | 0.88 |
| Transaortic | 0.84 (0.66–1.07) | 0.15 | 1155.61 (0.0–inf) | 0.99 |
| Epicardial | 1.03 (0.78–1.35) | 0.86 | 1.25 (0.76–2.05) | 0.38 |
| Procedure time (min) | 1.18 (0.84–1.66) | 0.35 | 0.94 (0.36–2.45) | 0.91 |
| Radiation duration (min) | 1.23 (0.87–1.74) | 0.23 | 1.38 (0.53–3.61) | 0.51 |
| Inducible clinical VT | 1.04 (0.78–1.38) | 0.78 | 1.15 (0.54–2.44) | 0.72 |
| ≥1 inducible morphology | 1.11 (0.81–1.51) | 0.53 | 0.91 (0.5–1.67) | 0.76 |
| VTCL (ms) | 1.3 (0.97–1.74) | 0.08 | 0.67 (0.3–1.52) | 0.34 |
| Elimination of all inducible VTs | 1.04 (0.78–1.4) | 0.78 | 1.07 (0.54–2.09) | 0.85 |
| Complications | 1.14 (0.89–1.46) | 0.31 | 0.94 (0.51–1.75) | 0.84 |
P < 0.05 considered significant. BMI, body mass index; COPD, chronic obstructive pulmonary disease; SCD, sudden cardiac death; CAD, coronary artery disease; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; AMI, acute myocardial infarction; ICD, implantable cardioverter defibrillator; CRT, implanted cardiac resynchronization therapy device; DCM, dilated cardiomyopathy; iDCM, ischemic dilated cardiomyopathy; niDCM, non-ischemic dilated cardiomyopathy; NYHA, New York Heart Association functional class prior to the ablation; LVEF, left ventricular ejection fraction; LVEDD, left ventricular end diastolic diameter; LVESD, left ventricular end systolic diameter; RVEDD, right ventricular end diastolic diameter; TAPSE, tricuspid annular plane systolic excursion; E/A, transmitral E and A wave ratio; DT, transmitral E wave deceleration time; MR, mitral regurgitation; TR, tricuspid regurgitation; PASP, pulmonary artery systolic pressure; GFR, glomerulus filtration rate; MRA, mineralocorticoid-receptor antagonist therapy; ACEi/ARB, angiotensin-convertase enzyme inhibitor or angiotensin-receptor blocker therapy, AAD, anti-arrhythmic drug; HD, hemodynamic; VT, ventricular tachycardia; VTCL, ventricular tachycardia cycle length. Bold values indicate statistically significant results.